Radiotherapy Potentiates the Therapeutic Efficacy of Intratumoral Dendritic Cell Administration

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8466-8475

  Teitz Tennenbaum, Seagal ^a   Li, Qiao ^a   Rynkiewicz, Susan ^a   Ito, Fumito ^a   Davis, Mary A ^a   McGinn, Cornelius J ^a   Chang, Alfred E ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b 3302 Cancer Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; LUNG METASTASIS; LUNG TUMOR; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SPLEEN CELL; TUMOR GROWTH; TUMOR NECROSIS; TUMOR REGRESSION;

ANIMALS; APOPTOSIS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NECROSIS;

EID: 0345734266     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Schuler, G., and Steinman, R. M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med., 186: 1183-1187, 1997.
2. Nestle, F. O. Dendritic cell vaccination for cancer therapy. Oncogene. 19: 6673-6679, 2000.
3. Fields, R. C., Shimizu, K., and Mule, J. J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 95: 9482-9487, 1998.
4. Labarriere, N., Bretaudeau, L., Gervois, N., Bodinier, M., Bougras, G., Diez, E., Lang, F., Gregoire, M., and Jotereau, F. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int. J. Cancer, 101: 280-286, 2002.
5. Boczkowski, D., Nair, S. K., Snyder, D., and Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med., 184: 465-472, 1996.
6. Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., Angevin, E., Amigorena, S., and Zitvogel, L. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med., 7: 297-303, 2001.
7. Mayordoma, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Garcia-Prats, M. D., DeLeo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat. Med., 1: 1-6, 1995.
8. Gong, J., Nikrui, N., Chen, D., Koido, S., Wu, Z., Tanaka, Y., Cannistra, S., Avigan, D., and Kufe, D. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol., 165: 1705-1711, 2000.
9. Chang, A. E., Redman, B., G., Whitfield, J. R., Nickoloff, B. J., Braun, T. M., Lee, P. T., Geiger, J. D., and Mulay, J. J. A Phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res., 8: 1021-1032, 2002.
10. Geiger, J. D., Hutchinson, R. J., Hohenkirk, L. F., McKenna, E. A., Yanik, G. A., Levine, J. E., Chang, A. E., Braun, T. M., and Mule, J. J. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res., 61: 8513-8519, 2001.
11. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
12. Marten, A., Flieger, D., Renoth, S., Weineck, S., Albers, P., Compes, M., Schottker, B., Ziske, C., Engelhart, S., Hanfland, P., Krizek, L., Faber, C., von Ruecker, A., Muller, S., Sauerbruch, T., and Schmidt-Wolf, I. G. H. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/II trial. Cancer Immunol. Immunother., 51: 637-644, 2002.
13. Stift, A., Friedl, J., Dubsky, P., Bachleitner-Hofmann, T., Schueller, G., Zontsich, T., Benkoe, T., Radelbauer, K., Brostjan, C., Jakesz, R., and Gnant, M. Dendritic cell-based vaccination in solid cancer. J. Clin. Oncol., 21: 135-142, 2003.
14. Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., Pineiro, L., Steinman, R., and Fay, J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res., 61: 6451-6458, 2001.
15. Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C. A., Becker, V., Gross, A. J., Hemmerlein, B., Kanz, L., Muller, G. A., and Ringert, R. H. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med., 6: 332-336, 2000.
16. Friedman, E. J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr. Pharm. Des., 8: 1765-1780, 2002.
17. Matzinger, P. Tolerance, danger, and the extended family. Annual Rev. Immunol., 12: 991-1045, 1994.
18. Dieu-Nosjean, M. C., Vicari, A., Lebecque, S., and Caux, C. Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J. Leukocyte Biol., 66: 252-262, 1999.
19. Strome, S. E., Voss, S., Wilcox, R., Wakefield, T. L., Tamada, K., Flies, D., Chapoval, A., Lu, J., Kasperbauer, J. L., Padley, D., Vile, R., Gastineau, D., Wettstein, P., and Chen, L. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res., 62: 1884-1889, 2002.
20. Nishioka, Y., Hirao, M., Robbins, P. D., Lotze, M. T., and Tahara, H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res., 59: 4035-4041, 1999.
21. Candido, K. A., Shimizu, K., McLaughlin, J. C., Kunkel, R., Fuller, J. A., Redman, B. G., Thomas, E. K., Nickoloff, B. J., and Mule, J. J. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res., 61: 228-236, 2001.
22. Arca, M. J., Krauss, J. C., Aruga, A., Cameron, M. J., Shu, S., and Chang, A. E. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther., 3: 39-47, 1996.
23. Barth, R. J., Bock, S. N., Mule, J. J., and Rosenberg, S. A. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J. Immunol., 144: 1531-1537, 1990.
24. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods. 184: 39-51, 1995.
25. Albert, M. L., Sauter, B., and Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class 1-restricted CTLs. Nature (Lond.), 392: 86-89, 1998.
26. Nair, S., Snyder, D., Rouse, B. T., and Gilboa, E. Regression of tumors in mice vaccinated with professional antigen presenting cells pulsed with tumor extracts. Cancer (Phila.), 70: 706-715, 1997.
27. Shimizu, K., Fields, R. C., Giedlin, M., and Mule, J. J. Systemic administration of inlerleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA, 96: 2268-2273, 1999.
28. Son, Y. I., Mailliard, R. B., Watkins, S. C., and Lotze, M. T. Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti-tumor effects when combined with interleukin-2. Laryngoscope, 111: 1472-1478, 2001.
29. Aruga, A., Aruga, E., Tanigawa, K., Bishop, D. K., Sondak, V. K., and Chang, A. E. Type 1 versus type 2 cytokine release by VβT cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol., 159: 664-673, 1997.
30. Barth, R. J., Mule, J. J., Spiess, P. J., and Rosenberg, S. A. Interferon γ and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med., 173: 647-658, 1991.
31. Itoh, T., Storkus, W. J., Gorelik, E., and Lotze, M. T. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. J. Immunol., 153: 1202-1215, 1994.
32. Dematos, P., Abdel-Wahab, Z., Vervaert, C., Hester, D., and Seigler, H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B 16 tumors in mice. J. Surg. Oncol., 68: 79-91, 1998.
33. Sauter, B., Albert, M. L., Francisco, L., Larsson, M., Somersan, S., and Bhardwaj, N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med., 191: 423-434, 2000.
34. Lotze, M. T. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann. Surg., 226: 1-5, 1997.
35. Gabrilovich, D. I., Ciernik, I. F., and Carbone, D. P. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol., 170: 101-110, 1996.
36. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D., and Carbone, D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.
37. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2: 1096-1103, 1996.
38. Gabrilovich, D. I., Nadaf, S., Corak, J., Berzofsky, J. A., and Carbone, D. P. Dendritic cells in antitumor immune responses. 11. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell. Immunol., 170: 111-119, 1996.
39. Nikitina, E. Y., and Gabrilovich, D. I. Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int. J. Cancer. 94: 825-833, 2001.
40. Kleindienst, P., and Brocker, T. Endogenous dendritic cells are required for amplification of T cell responses induced by denritic cell vaccine in vivo. J. Immunol., 170: 2817-2823, 2003.
41. Triozzi, P. L., Khurram, R., Aldrich, W. A., Walker, M. J., Kim, J. A., and Jaynes, S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer (Phila.). 89: 2646-2654, 2000.
42. Tanaka, F., Yamaguchi, H., Ohta, M., Mashino, K., Sonoda, H., Sadanaga, N., Inoue, H., and Mori, M. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int. J. Cancer. 101: 265-269, 2002.
43. Yu, B., Kusmartsev, S., Cheng, F., Paolini, M., Nefedova, Y., Sotomayor, E., and Gabrilovich, D. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin. Cancer Res., 9: 285-294, 2003.
44. Dewey, W. C., Ling, C. C., and Meyn, R. E. Radiation-induced apoptosis: relevance to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 33: 781-796, 1995.
45. Jonathan, E. C., Bernhard, E. J., and McKenna, W. G. How does radiation kill cells? Cur. Opin. Chem. Biol., 3: 77-83, 1999.
46. Kotera, Y., Shimizu, K., and Mule, J. J. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res., 61: 8105-8109, 2001.
47. Celluzzi, C. M., and Falo, L. D., Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol., 160: 3081-3085, 1998.
48. Heckmann, M., Douwes, K., Peter, R., and Degitz, K. Vascular activation of adhesion molecule mRNA and cell surface expression by ionizing radiation. Exp. Cell Res., 238: 148-154, 1998.
49. Quarmby, S., Kumar, P., and Kumar, S. Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte-endothelial cell interactions. Int. J. Cancer. 82: 385-395, 1999.
50. Ganss, R., Ryschich, E., Klar, E., Arnold, B., and Hammerling, G. J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res., 62: 1462-1470, 2002.
51. Gallucci, S., and Matzinger, P. Danger signals: SOS to the immune system. Cur. Opin. Immunol., 13: 114-119, 2001.
52. Kikuchi, T., Moore, M. A. S., and Crystal, R. G. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood, 96: 91-99, 2000.